BUSINESS SEGMENT INFORMATION

9 Months Ended

Sep. 30, 2012

Segment Reporting [Abstract]

Business Segment Information [Text Block]

Note 2. BUSINESS SEGMENT INFORMATION

BMS operates in a single segment engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of innovative medicines that help patients prevail over serious diseases. A global research and development organization and a global supply chain organization are utilized and responsible for the development and delivery of products to the market. Products are distributed and sold through regional organizations that serve the United States; Europe; Latin America, Middle East and Africa; Japan, Asia Pacific and Canada; and Emerging Markets defined as Brazil, Russia, India, China and Turkey. The business is also supported by global corporate staff functions. Segment information is consistent with the financial information regularly reviewed by the chief operating decision maker, the chief executive officer, for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting future periods.

Net sales of key products were as follows:

		Three Months Ended September 30,				Nine Months Ended September 30,
Dollars in Millions		2012		2011		2012		2011
Plavix* (clopidogrel bisulfate)		$	64	$	1,788	$	2,498	$	5,415
Avapro*/Avalide* (irbesartan/irbesartan-hydrochlorothiazide)			95		216		419		757
Eliquis (apixaban)			-		-		1		-
Abilify* (aripiprazole)			676		691		2,008		2,021
Reyataz (atazanavir sulfate)			363		391		1,127		1,153
Sustiva (efavirenz) Franchise			370		359		1,144		1,073
Baraclude (entecavir)			346		311		1,028		878
Erbitux* (cetuximab)			173		172		531		510
Sprycel (dasatinib)			263		211		738		576
Yervoy (ipilimumab)			179		121		495		216
Orencia (abatacept)			307		233		851		660
Nulojix (belatacept)			3		-		7		2
Onglyza/Kombiglyze (saxagliptin/saxagliptin and metformin)			178		127		511		320
Byetta* (exenatide)			55		-		55		-
Bydureon* (exenatide extended-release for injectable suspension)			20		-		20		-
Mature Products and All Other			644		725		1,997		2,209
	Net Sales	$	3,736	$	5,345	$	13,430	$	15,790